Tenaya Therapeutics, (id:8084 TNYA)

2.38 USD

Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/24/2024 2:44:32 PM)

Exchange closed, opens in 18 hours 45 minutes

• 1 day
• 1 week
• 1 month
• 6 months
• 1 year
• All

About Tenaya Therapeutics,

Market Capitalization 188.54M

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.